, Figure 5 Analyse en sous-groupe: Forest Plot pour la survie globale. Abréviations: PC=Paclitaxel + cetuximab, P=Paclitaxel, IC95%= Intervalle de confiance à 95%

, Figure 6 Analyse en sous-groupe: Forest Plot pour la survie sans progression, Abréviations: PC=Paclitaxel + cetuximab, P=Paclitaxel, IC95%= Intervalle de confiance à 95%

A. Argiris, M. V. Karamouzis, D. Raben, and R. L. Ferris, Head and neck cancer. The Lancet, vol.371, pp.1695-709, 2008.

J. B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-rubio et al., Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy, J Clin Oncol, vol.25, issue.16, pp.2171-2178, 2007.

J. B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki et al., Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer, N Engl J Med, vol.359, issue.11, pp.1116-1143, 2008.

. Grau-j-josé, M. Caballero, E. Verger, M. Monzó, J. Blanch et al., Weekly paclitaxel for platinresistant stage IV head and neck cancer patients, Acta Otolaryngol, 2009.

J. Fayette, A. Montella, S. Chabaud, T. Bachelot, P. Pommier et al., Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution: Anticancer Drugs, vol.21, pp.553-561, 2010.

A. D. Colevas, S. S. Yom, D. G. Pfister, S. Spencer, D. Adelstein et al., NCCN Guidelines Insights: Head and Neck Cancers, Version 1, J Natl Compr Canc Netw, vol.16, issue.5, pp.479-90, 2018.

W. C. Rose, Therapeutic Synergy of Oral Taxane BMS-275183 and Cetuximab versus Human Tumor Xenografts, Clin Cancer Res, vol.10, issue.21, pp.7413-7420, 2004.

R. Hitt, A. Irigoyen, H. Cortes-funes, J. J. Grau, J. A. García-sáenz et al., Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck, Ann Oncol, vol.23, issue.4, pp.1016-1038, 2012.

T. Enokida, S. Okano, T. Fujisawa, Y. Ueda, S. Uozumi et al., Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck, Front Oncol, vol.8, p.339, 2018.

J. Péron, P. Ceruse, E. Lavergne, G. Buiret, B. Pham et al., Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma, 2012.

B. Jiménez, J. M. Trigo, B. I. Pajares, M. I. Sáez, C. Quero et al., Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients, Oral Oncol, vol.49, issue.2, pp.182-187, 2013.

P. Therasse, S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI J Natl Cancer Inst, vol.92, issue.3, pp.205-221, 2000.

D. Soulières, S. Faivre, R. Mesía, É. Remenár, S. Li et al., Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebocontrolled phase 2 trial, Lancet Oncol, vol.18, issue.3, pp.323-358, 2017.

R. L. Ferris, G. Blumenschein, F. J. Guigay, J. Colevas, A. D. Licitra et al., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N Engl J Med, vol.375, issue.19, pp.1856-67, 2016.

R. Mehra, T. Y. Seiwert, S. Gupta, J. Weiss, I. Gluck et al., Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012, Br J Cancer, vol.119, issue.2, pp.153-162, 2018.

B. Burtness, K. J. Harrington, R. Greil, D. Soulières, M. Tahara et al., LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), Ann Oncol [Internet], 2018.

S. E. Park, S. H. Lee, J. S. Ahn, M. Ahn, K. Park et al., Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer, J Thorac Oncol, vol.13, issue.1, pp.106-117, 2018.

K. Saleh, A. Daste, N. Martin, E. Pons-tostivint, A. Auperin et al., Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck, J Clin Oncol, vol.36, issue.15_suppl, pp.6015-6015, 2018.

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs

, Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés